Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Digs Into Specifics Of CMS Proposal For Covering Clinical Trial Costs

This article was originally published in The Gray Sheet

Executive Summary

Device industry representatives say CMS' latest proposed revision of its policy for covering certain clinical trial costs is a significant improvement over the previous proposal, but claim some specific requirements would be too burdensome on manufacturers

You may also be interested in...



CMS Maintains Status Quo On Clinical Trial Coverage, Again

Under intense pressure from Congress, industry and the medical research community, CMS has decided to maintain the status quo for coverage of routine costs in clinical trials

CMS Maintains Status Quo On Clinical Trial Coverage, Again

Under intense pressure from Congress, industry and the medical research community, CMS has decided to maintain the status quo for coverage of routine costs in clinical trials

Medicare In Brief

MedCAC priority list: The Medicare Evidence Development and Coverage Advisory Committee will convene Oct. 22 to develop a list of priority research topics with the most potential impact on the Medicare program and its beneficiaries. The list will be a framework for the scientific community to advance evidence development, CMS says...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel